American Tower Corporation (NYSE:AMT) is one of the best dividend stocks in the real estate sector. On November 17, Vikram Malhotra, a Mizuho Securities analyst, was bullish on AMT. He assigned a Buy ...
The Renault Kwid would be a good option for you. As far as AMTs go, the Kwid's gearbox does the job, but the car itself will feel like a bit of an upgrade over your current Maruti Alto. The Kwid has a ...
The AutoMag was first designed for the rimless .44 AMP cartridge, but soon after its debut the company introduced the .357 AMP, created by necking the .44 case down to accept .357-caliber bullets. The ...
American Tower (AMT) shares have seen some movement recently, catching the attention of investors interested in real estate and infrastructure stocks. With recent performance trends, many are ...
Understanding the differences between AMT, CVT and DCT can help you choose the appropriate transmission for your needs. Choosing the right car transmission can be confusing. With so many options ...
The manual gearbox is dying, but in certain regions, it has a new lease of life as it is being replaced by the AMT — Automated Manual Transmission. While AMTs may not be common in the United States, ...
SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Multitude Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of ADC drugs, today announced interim results from its ...
Leeds United midfielder Sean Longstaff has been voted the AMT Auto Player of the Month for September, following a series of standout performances in the Premier League. Longstaff topped the fan poll ...
On Tuesday, the IRS released Notice 2025-49, which provides interim guidance regarding the application of the CAMT. The proposed regulations address the application of the CAMT and technical ...
American Tower’s (NYSE:AMT) growth outlook remains tied to muted carrier activity, with T-Mobile US (NASDAQ:TMUS) driving colocations to meet Federal Communications Commission (FCC) buildout rules ...
UniQure Gene Therapy’s Clinical Trial Results Keep It on Path to Become First Huntington’s Treatment
A uniQure gene therapy slowed progression of Huntington’s disease by 75% after three years, statistically significant clinical trial results the company says will support plans for a regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback